Maximum reduction in the sum of lesions and a single lesion after samalizumab dosing

Samalizumab Treatment GroupPatient IDSingle LesionbSum of Lesionsb
% ChangeCycle Day% ChangeCycle Day
50 mg/m2 (N = 4)101–103−3.45C1 D282.77C1 D28
101–104−45.29C1 D77−9.8C1 D35
102–101−19.75C4 D164.32C4 D16
102–102−9.77C1 D35−9.46C1 D35
100 mg/m2 (N = 4)a101–202−37.78C4 D0−6.83C4 D0
101–203−11.54C4 D07.0C1 D28
102–201−95.31C4 D0−20.7C4 D0
102–205−41.36C3 D26−18.7C3 D26
200 mg/m2 (N = 2)a101–301− 48.67C1 D28−28.7C1 D28
102–303−42.05C3 D21−4.75C3 D21
300 mg/m2 (N = 3)101–402−14.29C4 D438.3C4 D43
101–403−23.81C1 D29−12.5C1 D29
102–401−58.73C1 D35−16.1C16 D1
400 mg/m2 (N = 3)102–502−87.02C13 D35−63.4C13 D35
107–503−54.55C4 D27−3.34C1 D42
107–504−29.34C1 D299.52C1 D29
500 mg/m2 (N = 4)a101–606−48.15C6 D0−6.91C6 D0
102–601−86.36C2 D28−73.7C2 D28
102–603−5.13C1 D251.84C1 D25
102–607−37.36C1 D28−19.4C1 D28

aPatient 107–602 (500 mg/m2 cohort) did not have a post-dose CT scan and was not evaluable; Patients 104–204 (100 mg/m2 cohort) and 104–302 (200 mg/m2 cohort) had no reduction in any of their target lesions and are not included

bMaximum reduction for a single lesion (product of bi-dimensional tumor measurement) and maximum reduction for sum of lesions (sum of the products of bi-dimensional tumor measurements) are presented as a % Change from baseline on the indicated Cycle and Day